Abstract
Antibiotic resistance of bacterial pathogens isolated in China is a major concern. Omadacycline is a novel tetracycline derivative that has been approved for use in skin infections and community-acquired pneumonia. This study was conducted to determine the in vitro activity of omadacycline against a large collection of patient isolate medical centers across Mainland China. A total of 1041 recent clinical isolates are obtained from patients hospitalized in 29 provinces and municipalities across China. The in vitro activity of omadacycline and comparator agents was assessed using the microbroth dilution methodology. Omadacycline was active against methicillin-susceptible and -resistant Staphylococcus aureus with MIC90 values of 0.25 and 1 mg/L, respectively. All isolates of Enterococcus faecalis and Enterococcus faecium, including vancomycin-resistant isolates, were inhibited by ≤ 0.25 mg/L of omadacycline. It was active against Streptococcus pneumoniae irrespective of susceptibility to penicillin or macrolides (MIC90 =0.12 mg/L). The minimum inhibitory concentration (MIC) distribution of omadacycline was nearly identical against (extended-spectrum beta-lactamases) ESBL-positive, ESBL-negative, and carbapenemase-producing Escherichia coli (MIC90 = 4 mg/L). Omadacycline also showed good activity against Acinetobacter baumannii, inhibiting all isolates at ≤ 8 mg/L. Against Hemophilus influenzae and Moraxella catarrhalis, the MICs of omadacycline were low and not influenced by the presence of β-lactamase. Overall, the activity of omadacycline was very good against isolates commonly associated with skin infections and pneumonia, and the susceptibility of Chinese isolates was similar to that reported for these pathogens from large surveillance studies outside China. This suggests that omadacycline could be an option for treatment of these infections in Chinese patients.
Similar content being viewed by others
Data availability
Data can be provided upon request.
References
Karlowsky JA, Steenbergen J, Zhanel GG (2019) Microbiology and preclinical review of omadacycline. Clin Infect Dis 69(Supplement_1):S6–S15. https://doi.org/10.1093/cid/ciz395
Heidrich CG, Mitova S, Schedlbauer A, Connell SR, Fucini P, Steenbergen JN, Berens C (2016) The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome. Antibiotics (Basel) 5(4). https://doi.org/10.3390/antibiotics5040032
Huband MD, Pfaller MA, Shortridge D, Flamm RK (2019) Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY Antimicrobial Surveillance Programme, 2017. J Glob Antimicrob Resist 19:56–63. https://doi.org/10.1016/j.jgar.2019.02.017
Stapert L, Wolfe C, Shinabarger D, Marra A, Pillar C (2018) In vitro activities of omadacycline and comparators against anaerobic bacteria. Antimicrob Agents Chemother 62(4). https://doi.org/10.1128/aac.00047-18
O'Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E (2019) Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 380(6):528–538. https://doi.org/10.1056/NEJMoa1800170
O'Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E (2019) Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis 19(10):1080–1090. https://doi.org/10.1016/s1473-3099(19)30275-0
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E (2019) Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 380(6):517–527. https://doi.org/10.1056/NEJMoa1800201
Pfaller MA, Rhomberg PR, Huband MD, Flamm RK (2018) Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). Diagn Microbiol Infect Dis 91(2):179–183. https://doi.org/10.1016/j.diagmicrobio.2018.01.019
Pfaller MA, Rhomberg PR, Huband MD, Flamm RK (2018) Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Diagn Microbiol Infect Dis 90(2):143–147. https://doi.org/10.1016/j.diagmicrobio.2017.10.010
CLSI (2018) M07-A11 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Tenth edn. Clinical and Laboratory Standards Institute, Wayne
CLSI (2020) M100-S30 Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne, PA
Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F (2019) Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 63(4):e02431–e02418. https://doi.org/10.1128/aac.02431-18
Yezli S, Li H (2012) Antibiotic resistance amongst healthcare-associated pathogens in China. Int J Antimicrob Agents 40(5):389–397. https://doi.org/10.1016/j.ijantimicag.2012.07.009
Qiao M, Ying G-G, Singer AC, Zhu Y-G (2018) Review of antibiotic resistance in China and its environment. Environ Int 110:160–172. https://doi.org/10.1016/j.envint.2017.10.016
Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu L-F, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu J-H, Shen J (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16(2):161–168. https://doi.org/10.1016/S1473-3099(15)00424-7
Zhang QQ, Ying GG, Pan CG, Liu YS, Zhao JL (2015) Comprehensive evaluation of antibiotics emission and fate in the river basins of China: source analysis, multimedia modeling, and linkage to bacterial resistance. Environ Sci Technol 49(11):6772–6782. https://doi.org/10.1021/acs.est.5b00729
Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ (2006) Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Glob Health 2(1):6. https://doi.org/10.1186/1744-8603-2-6
Zhen X, Stålsby Lundborg C, Sun X, Hu X, Dong H (2019) The clinical and economic impact of antibiotic resistance in China: a systematic review and meta-analysis. Antibiotics 8(3):115. https://doi.org/10.3390/antibiotics8030115
Fluit AC, van Gorkum S, Vlooswijk J (2019) Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants. Diagn Microbiol Infect Dis 94(1):78–80. https://doi.org/10.1016/j.diagmicrobio.2018.11.010
Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, Tanaka SK, Levy SB (2014) In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58(2):1127–1135. https://doi.org/10.1128/aac.01242-13
NUZYRA (omadacycline) prescribing information. (2019). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf.
Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS (2019) Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and Taiwan: results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016). Antimicrob Agents Chemother 63(3):e02262–e02218. https://doi.org/10.1128/aac.02262-18
Chen CJ, Huang YC (2014) New epidemiology of Staphylococcus aureus infection in Asia. Clin Microbiol Infect 20(7):605–623. https://doi.org/10.1111/1469-0691.12705
Du J, Chen C, Ding B, Tu J, Qin Z, Parsons C, Salgado C, Cai Q, Song Y, Bao Q, Zhang L, Pan J, Wang L, Yu F (2011) Molecular characterization and antimicrobial susceptibility of nasal Staphylococcus aureus isolates from a Chinese medical college campus. PLoS One 6(11):e27328. https://doi.org/10.1371/journal.pone.0027328
Wu D, Wang Q, Yang Y, Geng W, Wang Q, Yu S, Yao K, Yuan L, Shen X (2010) Epidemiology and molecular characteristics of community-associated methicillin-resistant and methicillin-susceptible Staphylococcus aureus from skin/soft tissue infections in a children’s hospital in Beijing, China. Diagn Microbiol Infect Dis 67(1):1–8. https://doi.org/10.1016/j.diagmicrobio.2009.12.006
Code availability
Not applicable.
Funding
This study was funded in part by National Mega-project for Innovative Drugs (2019ZX09721001-006-004) and CHINET Antimicrobial Surveillance Network (grant WI207259). It was also funded by Zai Laboratory Inc., Shanghai, China.
Author information
Authors and Affiliations
Contributions
All authors made substantial contributions to the conception or design of the work.
Corresponding author
Ethics declarations
Conflict of interest
Antimicrobial development specialists, LLC, was contracted to during 2019 to perform services for Boston Pharma, Carb-X, Colgate Palmolive, ContraFect Corp., Emergent Biosciences, Entasis Therapeutics, EXDA, Nabriva, NacuGen, Novartis, RecreoPharma, Sihuan Pharmaceutical, SuperTrans Medical, Tetraphase, Theravance, University of Waterloo, Wellcome Trust, X-Biotix, and Zai Labs.
Ethical approval
This study was approved by the Institutional Review Board of Huashan Hospital, Fudan University (Number: 2018-349).
Consent to participate
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Dong, D., Zheng, Y., Chen, Q. et al. In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018. Eur J Clin Microbiol Infect Dis 39, 1559–1572 (2020). https://doi.org/10.1007/s10096-020-03877-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-020-03877-w